Boston, MA 06/20/2014 (wallstreetpr) – BIND Therapeutics Inc (NASDAQ:BIND), a nanomedicine company based in Cambridge, has announced its latest collaborative arrangement with another large drug company. It announced a partnership with Roche, a Swiss drug giant, to develop novel treatments, but outside its usual oncology therapeutic area.
Bind is best known for developing of programmable treatments for certain types of cancer. The company develops Accurins, which is a precise delivery technology that targets specific cells or tissues for drug concentration while keeping healthy tissues safe from adverse effects. The technology has grown popular in various treatments, and the company has entered several partnerships based on the technology.
Roche deal
BIND Therapeutics Inc (NASDAQ:BIND) did not disclose the terms of the collaborative agreement with Roche. However, Bind said the latest agreement further validates the wide-range potential of its Accurins technology. The combination of Bind’s nanomedicine platform with the deep expertise of Roche in developing treatments, especially in the unmet medical areas, has the potential of leading to significant health benefits to patients while driving value for the respective shareholders.
BIND Therapeutics Inc (NASDAQ:BIND) already has Accurins-based agreements with drug companies such as Pfizer Inc (NYSE:PFE), Amgen, Inc. (NASDAQ:AMGN) and AstraZeneca plc (ADR) (NYSE:AZN).
In addition to deal
BIND Therapeutics is not letting serious opportunities slip from its fingers. The company is also developing a drug candidate that is targeted at the treatment of non-small cell lung cancer. The drug also has promise for patients with metastatic castrate-resistant prostate cancer.
Through collaborative arrangements, the company expects to take its novel technology to new therapeutic areas so that it can impact more lives. Furthermore, partnerships have the potential of attracting more revenue for the company. With Accurins gaining popularly among drug makers, it remains to be seen who next moves to seal the deal with BIND Therapeutics Inc (NASDAQ:BIND) for the technology, which can significantly help in dealing with complex diseases as such cancer.
